라이트닝 바카라 사이트

Keytruda (Pembrolizumab), an immunotherapy anticancer drug, dominated South Korean pharmaceutical 라이트닝 바카라 사이트 last year, claiming the top spot. With approvals for 26 indications, it continues to lead in this category, recording approximately 2 million in 라이트닝 바카라 사이트. This marks a significant 66.4% increase compared to 2022. Notably, its success is attributed to the demonstrated survival improvement effect in renal cancer adjuvant therapy. Anticipation surrounds the drug's potential for reimbursement inclusion, given its impact on patients previously treated with conventional therapies.

In the second position, the osteoporosis treatment Prolia (active ingredient Denosumab) trailed Keytruda with a 라이트닝 바카라 사이트 difference of 7 million. Prolia experienced a million increase compared to 2022. Since its initial reimbursement approval for primary therapy in April 2019, Prolia has expanded its 라이트닝 바카라 사이트, resulting in a one-step improvement in ranking from the previous year. The drug has also been suggested to have the potential to prevent type 2 diabetes in osteoporosis patients, according to National Institute of Health Insurance Research Database (NIHRD) data in Taiwan.

In April 2023, the pediatric coverage-expanded atopic dermatitis treatment Dupixent (active ingredient Dupilumab) secured the third position with approximately 6 million in 라이트닝 바카라 사이트, closely following Prolia. Subsequently, there were shifts in rankings among anticancer drugs. Perjeta (active ingredient Pertuzumab) and Tagrisso (active ingredient Osimertinib) recorded 라이트닝 바카라 사이트 of million and million, respectively. Reversing their positions from 2022 when Tagrisso was fifth and Perjeta was sixth, these two drugs now hold the fourth and fifth positions, respectively. Following them, drugs such as Gardasil 9, Opdivo, Tecentriq, Plavix, and Eutropin S secured positions within the top 10.

The systemic hormone preparation Eutropin S (active ingredient Somatrofin) recorded 라이트닝 바카라 사이트 of .7 million, marking an increase of approximately .2 million (about 49%) from the 2022 라이트닝 바카라 사이트 of .5 million. Eutropin S, classified as a pediatric growth hormone, is currently prescribed as a non-reimbursed medication. The significant growth in the market for growth hormone injections, driven by an increase in prescriptions for pediatric growth hormone medications at tertiary hospitals, has contributed to these meaningful results for Eutropin S.

Certain medications, like Eutropin S, experience a sudden rise in rankings due to significant 라이트닝 바카라 사이트 growth. A recent example is the macular degeneration treatment, Eylea (active ingredient Aflibercept), whose Korean patent expired on the 9th of January. Eylea secured the 19th position last year with 라이트닝 바카라 사이트 of about .4 million, marking an increase of approximately .2 million compared to the 2022 라이트닝 바카라 사이트 of .2 million. As South Korean pharmaceutical and biotech companies enter the Eylea biosimilar competition, attention is also drawn to the future landscape.

Samsung Bioepis obtained product approval from the Ministry of Food and Drug Safety (MFDS) on February 23rd for their ophthalmic disease treatment, Afilivu (active ingredient Aflibercept). With this approval, the company becomes the first in Korea to secure an Eylea biosimilar. Additionally, Celltrion and Samchundang Pharm are completing global phase 3 clinical trials for the Eylea biosimilar and are in the process of South Korean product approval evaluation.